Combined treatment with imatinib and the MEK inhibitor trametinib prolonged survival in mouse models of BCR-ABL-independent imatinib-resistant CML [53]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.